I think you answered the question. The basket trial was small and not focused on one cancer. It did speak to the potential impact of Leronlimab on high CCR5 expressing tumors but really only provided a signal for that. The mice will focus the lens and should provide an unequivocal result for Glioblastoma in particular, quickly and cheaply, which will likely allow a leapfrog over phase 1 into perhaps a phase 2 study to nail efficacy and dosing strategy. Given the lack of really useful agents for GBM I also wonder if the FDA might grant breakthrough therapy status. These trials get expensive and we will probably need a partnership for this. If the humanized mouse results lead to the same kind of results we had with TNBC before Leronlimab was trialed in humans with that indication, knowing there are already some provocative observations in that basket trial involving Glioblastoma, I have to imagine BP will be beating the doors down in downtown Vancouver to get an audience with Jay et al.

Emphasis on quickly and cheaply to generate buzz…that’s why we drop down to mouse level. I applaud the move. My bet: one arm of the mouse trial will be saved to run another maze but we get the cheese.